Q32 Bio (FRA:DB0) Stock Based Compensation: €4.70 Mil (TTM As of Mar. 2026)


FRA:DB0 Q32 Bio Inc FRA:DB0
17 GF Score
Price €11.33
! 6 Warning Signs
View Full Analysis

What is Q32 Bio Stock Based Compensation?

Q32 Bio FRA:DB0 -0.18% 17 Stock Based Compensation is €4.70 Mil as of Mar. 2026. GuruFocus rates FRA:DB0 with a GF Score™ of 17/100. The stock has 6 warning signs investors should review.

Q32 Bio's Stock Based Compensation for the three months ended in Mar. 2026 was €1.34 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €4.70 Mil.

Q32 Bio Stock Based Compensation Related Terms

Q32 Bio Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Q32 Bio's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio Stock Based Compensation Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.67 1.17 1.31 4.19 4.49

Q32 Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 1.10 1.00 1.26 1.34
FRA:DB0
17GF Score
Q32 Bio Inc FRA:DB0
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.70 Mil.

What does a Stock Based Compensation of €4.70 Mil mean?
Q32 Bio (FRA:DB0) has a Stock Based Compensation of €4.70 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Q32 Bio and its competitors.
Is Q32 Bio's Stock Based Compensation too high?
Q32 Bio's current Stock Based Compensation is €4.70 Mil. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Stock Based Compensation compare to CAMP and CDXS?
Q32 Bio's Stock Based Compensation of €4.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Q32 Bio and its competitors. Q32 Bio's current Stock Based Compensation is €4.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current Stock Based Compensation of €4.70 Mil. The current Stock Based Compensation is €4.70 Mil. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current Stock Based Compensation is €4.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges QTTB:USA
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for FRA:DB0

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.33
Price